

Please type a plus sign (+) inside this box →



#4
JC02 Rec'd PCT/PTO 2 8 MAR 2002

PTO/SB/21 (08-00)


Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/049,556	
	Filing Date	February 12, 2002	
	First Named Inventor	LITTLE, DAVID G.	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission	3	Attorney Docket Number	RICE-006
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Sub. for Form 1449A/PTO 9 References Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual Name	ALAN W. CANNON, Reg. No. 34,977		
Signature			
Date	March 18, 2002		

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: March 18, 2002.			
Typed or printed name	Martha Cisneros		
Signature		Date	March 18, 2002

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	MARTHA CISNEROS		
Signature		Date	March 15, 2002
SENCOD INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231		Attorney Docket	RICE006
		First Named Inventor	DAVID G. LITTLE, et al.
		Application Number	10/049,556
		Filing Date	February 12, 2002
		Intern. Appl Number	PCT/AU00/00982
		Intern. Filing Date	08/17/00
		Confirmation No.	N/A
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Title	DRUG FOR TREATING FRACTURES

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor RICE-006.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: March 18, 2002

By: 
 Alan W. Cannon
 Registration No. 34,977

BOZICEVIC, FIELD & FRANCIS LLP
 200 Middlefield Road, Suite 200
 Menlo Park, CA 94025
 Telephone: (650) 327-3400
 Facsimile: (650) 327-3231
 F:\FORMS\Patent Forms\IDS\IDS.doc

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/049,556	
			Filing Date	February 12, 2002	
			Intern. Application Number	PCT/AU00/00982	
			Intern. Filing Date	08/17/00	
			First Named Inventor	DAVID G. LITTLE	
			Group Art Unit	Unassigned	
Examiner Name	Unassigned				
Sheet	1	of	1	Attorney Docket Number	RICE006

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
		B7	WO96/39150A		Merck & Co., Inc.	12/12/1996		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	ABSTRACT: LOMBARDI, entitled "Clinical trials with bisphosphonates" Ann Ital Med Int. 1992 Jul-Sep; 7(3 Suppl): 158S-165S.	
	C2	GOODSHIP et al., entitled "Use of Bisphosphonate (pamidronate) to modulate fracture repair in ovine bone," Ann Oncology 1994; 5 Suppl 7:S53-5.	
	C3	LI et al. entitled "Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats," J Bone Miner Res. Vol. 14, Number 6, (1999): 969-79.	
	C4	RUSSELL et al., entitled "Bisphosphonates: from the laboratory to the clinic and back again," Bone 1999 Jul; 25(1):97-106	
	C5	GLORIEUX et al., entitled "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta," N. Engl. J Med 1998; Number 14, 339:947-52	
	C6	RAGGIO et al. entitled, "Alendronate reduces fractures without increasing bone strength in a growing mouse model of osteogenesis imperfecta," Proceedings of Paediatric Orthopaedic Society of North America May 1999. (Paper No. 66)	
	C7	GIULIANI et al., entitled "Bisphosphonates Stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo," Bone 1998, May; Vol. 22 (5): 455-61.	
	C8	MAYOR P., et al., entitled "Zolendroic acid is superior to pamidronate in the treatment of tumour-induced hypercalcaemia: a pooled analysis," Journal of Clinical Oncology, Vol. 19, No. 2, January 15, 2001: pp. 558-567	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.